Literature DB >> 28970361

NFκB-Mediated Invasiveness in CD133+ Pancreatic TICs Is Regulated by Autocrine and Paracrine Activation of IL1 Signaling.

Alice Nomura1,2, Vineet K Gupta1, Patricia Dauer1,3, Nikita S Sharma1,4, Vikas Dudeja1, Nipun Merchant1, Ashok K Saluja1, Sulagna Banerjee5.   

Abstract

Tumor-initiating cells (TIC) have been implicated in pancreatic tumor initiation, progression, and metastasis. Among different markers that define this cell population within the tumor, the CD133+ cancer stem cell (CSC) population has reliably been described in these processes. CD133 expression has also been shown to functionally promote metastasis through NF-κB activation in this population, but the mechanism is unclear. In the current study, overexpression of CD133 increased expression and secretion of IL1β (IL1B), which activates an autocrine signaling loop that upregulates NF-κB signaling, epithelial-mesenchymal transition (EMT), and cellular invasion. This signaling pathway also induces CXCR4 expression, which in turn is instrumental in imparting an invasive phenotype to these cells. In addition to the autocrine signaling of the CD133 secreted IL1β, the tumor-associated macrophages (TAM) also produced IL1β, which further activated this pathway in TICs. The functional significance of the TIC marker CD133 has remained elusive for a very long time; the current study takes us one step closer to understanding how the downstream signaling pathways in these cells regulate the functional properties of TICs.Implications: This study demonstrates the important role of tumor- and macrophage-derived IL1β stimulation in pancreatic cancer. IL1 signaling is increased in cells with CD133 expression, leading to increased NF-kB activity, EMT induction, and invasion. Increased invasiveness via IL1β stimulation is mediated by the upregulation of CXCR4 expression. The study highlights the importance of IL1-mediated signaling in TICs. Mol Cancer Res; 16(1); 162-72. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28970361      PMCID: PMC5752573          DOI: 10.1158/1541-7786.MCR-17-0221

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  38 in total

1.  KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma.

Authors:  Jianhua Ling; Ya'an Kang; Ruiying Zhao; Qianghua Xia; Dung-Fang Lee; Zhe Chang; Jin Li; Bailu Peng; Jason B Fleming; Huamin Wang; Jinsong Liu; Ihor R Lemischka; Mien-Chie Hung; Paul J Chiao
Journal:  Cancer Cell       Date:  2012-01-17       Impact factor: 31.743

Review 2.  The role of inflammation in pancreatic cancer.

Authors:  Simone Hausmann; Bo Kong; Christoph Michalski; Mert Erkan; Helmut Friess
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

Review 3.  The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions.

Authors:  Ron N Apte; Shahar Dotan; Moshe Elkabets; Malka R White; Eli Reich; Yaron Carmi; Xiaping Song; Tatyana Dvozkin; Yakov Krelin; Elena Voronov
Journal:  Cancer Metastasis Rev       Date:  2006-09       Impact factor: 9.264

Review 4.  Stem cells as the root of pancreatic ductal adenocarcinoma.

Authors:  Anamaria Balic; Jorge Dorado; Mercedes Alonso-Gómez; Christopher Heeschen
Journal:  Exp Cell Res       Date:  2011-11-15       Impact factor: 3.905

5.  Expression of the stem cell markers CD133 and nestin in pancreatic ductal adenocarcinoma and clinical relevance.

Authors:  Hyung-Seok Kim; Seon-Young Yoo; Kyung-Tae Kim; Jong-Tae Park; Hyun-Jong Kim; Jung-Chul Kim
Journal:  Int J Clin Exp Pathol       Date:  2012-10-01

Review 6.  Inflammation and gastrointestinal cancer: an overview.

Authors:  Hiroyuki Marusawa; Brendan John Jenkins
Journal:  Cancer Lett       Date:  2013-08-24       Impact factor: 8.679

7.  Interleukin-1 receptor antagonist decreases severity of experimental acute pancreatitis.

Authors:  J Norman; M Franz; J Messina; A Riker; P J Fabri; A S Rosemurgy; W R Gower
Journal:  Surgery       Date:  1995-06       Impact factor: 3.982

8.  IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation.

Authors:  Zhuonan Zhuang; Huai-Qiang Ju; Mitzi Aguilar; Takashi Gocho; Hao Li; Tomonori Iida; Harold Lee; Xiaoqiang Fan; Haijun Zhou; Jianhua Ling; Zhongkui Li; Jie Fu; Min Wu; Min Li; Davide Melisi; Yoichiro Iwakura; Kesen Xu; Jason B Fleming; Paul J Chiao
Journal:  Clin Cancer Res       Date:  2015-10-23       Impact factor: 12.531

9.  The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells.

Authors:  W Wang; J L Abbruzzese; D B Evans; L Larry; K R Cleary; P J Chiao
Journal:  Clin Cancer Res       Date:  1999-01       Impact factor: 12.531

10.  CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer.

Authors:  S Maeda; H Shinchi; H Kurahara; Y Mataki; K Maemura; M Sato; S Natsugoe; T Aikou; S Takao
Journal:  Br J Cancer       Date:  2008-03-18       Impact factor: 7.640

View more
  16 in total

Review 1.  CD133 as a regulator of cancer metastasis through the cancer stem cells.

Authors:  Geou-Yarh Liou
Journal:  Int J Biochem Cell Biol       Date:  2018-11-03       Impact factor: 5.085

Review 2.  Signaling Networks That Control Cellular Plasticity in Pancreatic Tumorigenesis, Progression, and Metastasis.

Authors:  Howard C Crawford; Marina Pasca di Magliano; Sulagna Banerjee
Journal:  Gastroenterology       Date:  2019-02-01       Impact factor: 22.682

3.  First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours.

Authors:  Debbie Robbrecht; Christiane Jungels; Morten Mau Sorensen; Iben Spanggaard; Ferry Eskens; Signe Ø Fretland; Tormod Kyrre Guren; Philippe Aftimos; David Liberg; Christer Svedman; Lars Thorsson; Neeltje Steeghs; Ahmad Awada
Journal:  Br J Cancer       Date:  2021-12-13       Impact factor: 9.075

Review 4.  Markers of pancreatic cancer stem cells and their clinical and therapeutic implications.

Authors:  Arkadiusz Gzil; Izabela Zarębska; Wiktor Bursiewicz; Paulina Antosik; Dariusz Grzanka; Łukasz Szylberg
Journal:  Mol Biol Rep       Date:  2019-09-05       Impact factor: 2.316

5.  Premobilization of CD133+ cells by granulocyte colony- stimulating factor attenuates ischemic acute kidney injury induced by cardiopulmonary bypass.

Authors:  Xiaoqiang Li; Qin Wan; Jie Min; Linjia Duan; Jin Liu
Journal:  Sci Rep       Date:  2019-02-21       Impact factor: 4.379

6.  Pin2 telomeric repeat factor 1-interacting telomerase inhibitor 1 (PinX1) inhibits nasopharyngeal cancer cell stemness: implication for cancer progression and therapeutic targeting.

Authors:  Chaosheng Yu; Fang Chen; Xiaoqi Wang; Zhimou Cai; Mengxue Yang; Qingwen Zhong; Jialian Feng; Junzheng Li; Congxiang Shen; Zhong Wen
Journal:  J Exp Clin Cancer Res       Date:  2020-02-07

Review 7.  Cancer stem cell-immune cell crosstalk in tumour progression.

Authors:  Defne Bayik; Justin D Lathia
Journal:  Nat Rev Cancer       Date:  2021-06-08       Impact factor: 60.716

8.  Inhibition of Stearoyl-CoA Desaturase Induces the Unfolded Protein Response in Pancreatic Tumors and Suppresses Their Growth.

Authors:  Kaitlin Skrypek; Steven Balog; Yoshihiro Eriguchi; Kinji Asahina
Journal:  Pancreas       Date:  2021-02-01       Impact factor: 3.243

9.  Long non-coding RNA GAS5 acts as proliferation "brakes" in CD133+ cells responsible for tumor recurrence.

Authors:  Nikita S Sharma; Prisca Gnamlin; Brittany Durden; Vineet K Gupta; Kousik Kesh; Vanessa T Garrido; Vikas Dudeja; Ashok Saluja; Sulagna Banerjee
Journal:  Oncogenesis       Date:  2019-11-18       Impact factor: 7.485

Review 10.  The Cancer Stem Cell in Hepatocellular Carcinoma.

Authors:  Lucas-Alexander Schulte; Juan Carlos López-Gil; Bruno Sainz; Patrick C Hermann
Journal:  Cancers (Basel)       Date:  2020-03-14       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.